We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
17th Feb 20217:00 amRNSFirst dosing for SLN360
15th Feb 20213:55 pmRNSHolding(s) in Company
15th Feb 20211:14 pmRNSHolding(s) in Company
12th Feb 20214:57 pmRNSHolding(s) in Company
12th Feb 20214:53 pmRNSHolding(s) in Company
12th Feb 202112:10 pmRNSAdditional Listing and Total Voting Rights
11th Feb 20215:29 pmRNSHolding(s) in Company
11th Feb 202111:06 amRNSHolding(s) in Company
8th Feb 20214:28 pmRNSAdditional listing and Total Voting Rights
5th Feb 20217:00 amRNSSilence Announces $45m Private Placement
29th Jan 20212:35 pmRNSAdditional listing and Total Voting Rights
25th Jan 202112:41 pmRNSAdditional listing and Total Voting Rights
7th Jan 20217:00 amRNSHoldings in Company
6th Jan 202111:08 amRNSGrant of Options
6th Jan 202110:08 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSBoard of Directors Appointment
6th Jan 20217:00 amRNSSilence Therapeutics Appoints Craig Tooman as CFO
5th Jan 20217:00 amRNSJanuary Conference Schedule
4th Jan 202111:45 amRNSHoldings in Company
15th Dec 202012:28 pmRNSHolding(s) in Company
4th Dec 20205:08 pmRNSAdditional listing and Total Voting Rights
3rd Dec 20209:45 amRNSDirector/PDMR Shareholding
3rd Dec 20209:44 amRNSDirector/PDMR Shareholding
17th Nov 20203:44 pmRNSAdditional listing and Total Voting Rights
16th Nov 20207:00 amRNSPositive pre-clinical data presented
2nd Nov 20207:00 amRNSSilence Therapeutics Appoints Dr. Marie Wikström
29th Oct 20204:41 pmRNSSecond Price Monitoring Extn
29th Oct 20204:36 pmRNSPrice Monitoring Extension
16th Oct 20202:05 pmRNSDirector/PDMR Shareholding
14th Oct 20201:15 pmRNSAdditional listing and Total Voting Rights
12th Oct 20203:49 pmRNSDirector/PDMR Shareholding
8th Oct 20207:00 amRNSChange to Executive Leadership Team
6th Oct 20204:25 pmRNSAdditional Listing and Total Voting Rights
1st Oct 20207:00 amRNSConference Participation
23rd Sep 20208:59 amRNSHolding(s) in Company
23rd Sep 20207:06 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
22nd Sep 20204:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:05 amRNSGrant of options
14th Sep 20207:00 amRNSSilence Therapeutics announces new CEO
14th Sep 20207:00 amRNS2020 interim results
8th Sep 20207:01 amRNSR&D update
8th Sep 20207:00 amRNSInstructions exchanging ordinary shares for ADSs
8th Sep 20207:00 amRNSCompletion of Nasdaq listing
7th Sep 20205:47 pmRNSHolding(s) in Company
4th Sep 20202:18 pmRNSHolding(s) in Company
3rd Sep 20207:00 amRNSSilence to Participate in US Investor Conferences
1st Sep 20207:00 amRNSSilence Therapeutics Notice of Results
21st Aug 20207:00 amRNSSilence Therapeutics Files Registration with SEC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.